NKGN (NKGen Biotech) EBITDA Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. NKGen Biotech's EBITDA for the three months ended in Sep. 2024 was $7.40 Mil. NKGen Biotech's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, NKGen Biotech's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.

NKGen Biotech EBITDA Margin % Historical Data

The historical data trend for NKGen Biotech's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech EBITDA Margin % Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

-4,859.39

-30,170.13

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of NKGen Biotech's EBITDA Margin %

For the Biotechnology subindustry, NKGen Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

NKGen Biotech EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

NKGen Biotech's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-80.999	/	0
	=	%

NKGen Biotech's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	7.402	/	0
	=	%

NKGen Biotech (OTCPK:NKGN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

NKGen Biotech EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.